Compare Crispr Therapeutics AG (CRSP) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Advanced Drainage Systems Inc — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while Advanced Drainage Systems Inc trades at $143.7 (market cap $10.83B). The key difference: Advanced Drainage Systems Inc is far larger — about 2.1× Crispr Therapeutics AG's market cap, and Advanced Drainage Systems Inc pays a 0.56% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WMS | |
|---|---|---|
Market Cap | $5.23B | $10.83B |
Sector | Health | Industrials |
52-Week High | $76.78 | $175.38 |
52-Week Low | $44.34 | $129.50 |
Enterprise Value | $3.65B | $12.44B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Advanced Drainage Systems (WMS) trades at $140.13, down 1.09% on the day, amid a bearish technical signal from moving averages. The company demonstrates strong profitability with a 14% net income margin and 24.9% ROE, supported by recent earnings beats. Revenue for fiscal 2025 was $2.90 billion, with cash flow from operations at $581.49 million. Analyst consensus is a Buy with a $185.86 price target, indicating significant upside potential from current levels.
The outlook for WMS is positive based on solid fundamentals and analyst optimism, though near-term technical weakness and competitive pressures pose risks. Investment appeal centers on earnings growth and market leadership in water management solutions, balanced by exposure to construction sector volatility and rising debt levels noted in 2026 projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
